Literature DB >> 22809962

The efficacy of Pelargonium sidoides in the treatment of upper respiratory tract infections in children with transient hypogammaglobulinemia of infancy.

Turkan Patiroglu1, Aydin Tunc, Hatice Eke Gungor, Ekrem Unal.   

Abstract

Transient hypogammaglobulinemia of infancy (THI), defined as prolongation of physiological hypogammaglobulinemia normally seen between the initial 3rd and 6th months of life, is one of the most common immune deficiencies of childhood. Recurrent upper respiratory tract infections (URTI) are rather common in this group of patients, and generally, antibiotic treatment is the usual choice, although viruses involved in most cases. Pelargonium sidoides extract a herbal drug with known immunmodulator, antiviral and antibacterial effects. In this randomized, placebo controlled, prospective, monocentric pilot study, 14 of 28 patients with a diagnosed THI, were given Pelargonium sidoides, while 14 were given placebo during the period of URTI. Before and after the treatment period of one week, complete blood count, prothrombin time, activated prothromboplastin time, serum alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, total and direct bilirubin levels were measured. Mothers were asked to fill in a questionnaire for the recovery of the clinical symptoms during the treatment. The results were evaluated and compared in both group to assess the effect of Pelargonium sidoides. As a conclusion, the Pelargonium sidoides group showed increased appetite. The Pelargonium sidoides were found to beneficial for the nasal congestion, recovery of daily and nocturnal cough but not found be significant. Further studies with large number of participants are necessary to highlight the effect of Pelargonium sidoides in children with transient hypogammaglobulinemia of infancy.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809962     DOI: 10.1016/j.phymed.2012.06.004

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  7 in total

1.  Treatment with EPs 7630, a Pelargonium Sidoides Root Extract, Is Effective and Safe in Patients with the Common Cold: Results From a Randomized, Double Blind, Placebo-Controlled Clinical Trial.

Authors:  David S Riley; Viktor G Lizogub; Marianne Heger; Petra Funk; Heiko Mueller; Walter Lehmacher
Journal:  Integr Med (Encinitas)       Date:  2019-02

Review 2.  Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children.

Authors:  Domenico Careddu; Andrea Pettenazzo
Journal:  Int J Gen Med       Date:  2018-03-08

3.  Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections.

Authors:  Georg Seifert; Juliette Brandes-Schramm; Andrea Zimmermann; Walter Lehmacher; Wolfgang Kamin
Journal:  BMC Pediatr       Date:  2019-04-23       Impact factor: 2.125

Review 4.  Evaluation of botanicals as potential COVID-19 symptoms terminator.

Authors:  Ufuk Koca Caliskan; Methiye Mancak Karakus
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.374

5.  Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials.

Authors:  Jia Yao; Yuan Zhang; Xian-Zhe Wang; Jia Zhao; Zhao-Jun Yang; Yu-Ping Lin; Lu Sun; Qi-Yun Lu; Guan-Jie Fan
Journal:  Front Public Health       Date:  2022-02-16

6.  Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells.

Authors:  Michael Roth; Lei Fang; Daiana Stolz; Michael Tamm
Journal:  PLoS One       Date:  2019-02-01       Impact factor: 3.240

Review 7.  Medicinal properties and conservation of Pelargonium sidoides DC.

Authors:  Mack Moyo; Johannes Van Staden
Journal:  J Ethnopharmacol       Date:  2014-01-21       Impact factor: 4.360

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.